Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: A novel antiangiogenic therapy

Biochemical and Biophysical Research Communications

Volumn 413, Issue 1, 2011, Pages 128-135

  Kamisasanuki, Taro ^a   Tokushige, Saori ^a   Terasaki, Hiroto ^a   Khai, Ngin Cin ^a   Wang, Yuqing ^a   Sakamoto, Taiji ^a   Kosai, Ken ichiro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; HGF (hepatocyte growth factor); Ocular disease; RNAi; Tetraspanin; VEGF (vascular endothelial growth factor)

Indexed keywords

ANTIBODY; CD9 ANTIBODY; CD9 ANTIGEN; GROWTH FACTOR RECEPTOR; INTEGRIN; MATRIX METALLOPROTEINASE 14; SCATTER FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA NEOVASCULARIZATION; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MATRIX METALLOPROTEINASE 14; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; RATS; RETINAL NEOVASCULARIZATION; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC;

MUS;

EID: 80052867439     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.068     Document Type: Article

References (30)

1. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003, 9:653-660.
2. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97:1093-1107.
3. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol. Scand. 2006, 84:282-288.
4. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
5. You W.K., McDonald D.M. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 2008, 41:833-839.
6. Bressler N.M., Chang T.S., Fine J.T., Dolan C.M., Ward J. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch. Ophthalmol. 2009, 127:13-21.
7. Kahook M.Y., Kimura A.E., Wong L.J., Ammar D.A., Maycotte M.A., Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg. Lasers Imaging 2009, 40:293-295.
8. Sabet-Peyman E.J., Heussen F.M., Thorne J.E., Casparis H., Patel S.J., Do D.V. Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg. Lasers Imaging 2009, 40:316-318.
9. Hemler M.E. Targeting of tetraspanin proteins-potential benefits and strategies. Nat. Rev. Drug Discovery 2008, 7:747-758.
10. Miyado K., Yamada G., Yamada S., Hasuwa H., Nakamura Y., Ryu F., Suzuki K., Kosai K., Inoue K., Ogura A., Okabe M., Mekada E. Requirement of CD9 on the egg plasma membrane for fertilization. Science 2000, 287:321-324.
11. Le Naour F., Rubinstein E., Jasmin C., Prenant M., Boucheix C. Severely reduced female fertility in CD9-deficient mice. Science 2000, 287:319-321.
12. Miyake M., Koyama M., Seno M., Ikeyama S. Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J. Exp. Med. 1991, 174:1347-1354.
13. Zvieriev V., Wang J.C., Chevrette M. Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells. Biochem. Biophys. Res. Commun. 2005, 337:498-504.
14. Hori H., Yano S., Koufuji K., Takeda J., Shirouzu K. CD9 expression in gastric cancer and its significance. J. Surg. Res. 2004, 117:208-215.
15. Barreiro O., Yanez-Mo M., Sala-Valdes M., Gutierrez-Lopez M.D., Ovalle S., Higginbottom A., Monk P.N., Cabanas C., Sanchez-Madrid F. Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation. Blood 2005, 105:2852-2861.
16. Pekovic V., Harborth J., Broers J.L., Ramaekers F.C., van Engelen B., Lammens M., von Zglinicki T., Foisner R., Hutchison C., Markiewicz E. Nucleoplasmic LAP2alpha-lamin A complexes are required to maintain a proliferative state in human fibroblasts. J. Cell Biol. 2007, 176:163-172.
17. Ikoma T., Takahashi T., Nagano S., Li Y.M., Ohno Y., Ando K., Fujiwara T., Fujiwara H., Kosai K. A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin. Cancer Res. 2004, 10:1192-1200.
18. Kamizono J., Nagano S., Murofushi Y., Komiya S., Fujiwara H., Matsuishi T., Kosai K. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res. 2005, 65:5284-5291.
19. Yuge K., Takahashi T., Nagano S., Terazaki Y., Murofushi Y., Ushikoshi H., Kawai T., Khai N.C., Nakamura T., Fujiwara H., Kosai K. Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma. Int. J. Oncol. 2005, 27:77-85.
20. Takahashi T., Kawai T., Ushikoshi H., Nagano S., Oshika H., Inoue M., Kunisada T., Takemura G., Fujiwara H., Kosai K. Identification and isolation of embryonic stem cell-derived target cells by adenoviral conditional targeting. Mol. Ther. 2006, 14:673-683.
21. Khai N.C., Takahashi T., Ushikoshi H., Nagano S., Yuge K., Esaki M., Kawai T., Goto K., Murofushi Y., Fujiwara T., Fujiwara H., Kosai K. In vivo hepatic HB-EGF gene transduction inhibits Fas-induced liver injury and induces liver regeneration in mice: a comparative study to HGF. J. Hepatol. 2006, 44:1046-1054.
22. Deissler H., Kuhn E.M., Lang G.E. Tetraspanin CD9 is involved in the migration of retinal microvascular endothelial cells. Int. J. Mol. Med. 2007, 20:643-652.
23. Rogers M.S., Birsner A.E., D'Amato R.J. The mouse cornea micropocket angiogenesis assay. Nat. Protoc. 2007, 2:2545-2550.
24. Shen J., Samul R., Silva R.L., Akiyama H., Liu H., Saishin Y., Hackett S.F., Zinnen S., Kossen K., Fosnaugh K., Vargeese C., Gomez A., Bouhana K., Aitchison R., Pavco P., Campochiaro P.A. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006, 13:225-234.
25. Sulpice E., Ding S., Muscatelli-Groux B., Berge M., Han Z.C., Plouet J., Tobelem G., Merkulova-Rainon T. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol. Cell 2009, 101:525-539.
26. Murayama Y., Shinomura Y., Oritani K., Miyagawa J., Yoshida H., Nishida M., Katsube F., Shiraga M., Miyazaki T., Nakamoto T., Tsutsui S., Tamura S., Higashiyama S., Shimomura I., Hayashi N. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J. Cell. Physiol. 2008, 216:135-143.
27. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J. Cell Sci. 2001, 114:4143-4151.
28. Galvez B.G., Matias-Roman S., Yanez-Mo M., Vicente-Manzanares M., Sanchez-Madrid F., Arroyo A.G. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol. Biol. Cell 2004, 15:678-687.
29. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., Horwitz A.R. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
30. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96:1788-1795.